Can online therapy help scleroderma patients manage daily life?
NCT ID NCT07661836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether a personalized online occupational therapy program is feasible and helpful for adults with scleroderma. Twenty-four participants in Spain will either receive eight online therapy sessions over four weeks plus usual care, or usual care alone. The study focuses on whether people can complete the program and if it improves daily functioning and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized online occupational therapy sessions
- What this could lead to
- If it works, this could provide a convenient, home-based way to help people with scleroderma manage daily tasks and improve their quality of life.
- What could go wrong
- This is a very small pilot study (24 people) testing feasibility, not effectiveness. The intervention is short (4 weeks) and may not show lasting benefits or work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universidad de Zaragoza
Zaragoza, Zaragoza / Aragón, 50009, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.